iShares Genomics Immunology and Healthcare ETF
IDNA
4 hedge funds and large institutions have $6.68M invested in iShares Genomics Immunology and Healthcare ETF in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
26.6% more ownership
Funds ownership: 0% → 26.6% (+27%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.26M |
| 2 |
Jane Street
New York
|
+$852K |
| 3 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$182K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.37K |
Top Sellers
IDNA Hedge Fund Activity: Q2 2019 in Review
4 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q2 2019, worth a combined $6.68M.
Buyers outnumbered sellers: 4 funds opened new IDNA positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $5.26M.
- 4 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $6.68M of iShares Genomics Immunology and Healthcare ETF stock for Q2 2019.
- 4 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q2 2019 and 0 closed out, a net change of +4 holders.
- The largest iShares Genomics Immunology and Healthcare ETF buyer in Q2 2019 was BlackRock, an estimated $5.26M added.
Based on aggregated 13F filings for Q2 2019.